Concise review: Tissue-engineered vascular grafts for cardiac surgery: Past, present, and Future

Stem Cells Translational Medicine

Volumn 1, Issue 7, 2012, Pages 566-571

  Kurobe, Hirotsugu ^a   Maxfield, Mark W ^a   Breuer, Christopher K ^a   Shinoka, Toshiharu ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac surgery; Congenital heart defects; Stem cells; Tissue engineering

Indexed keywords

POLYGLYCOLIC ACID; POLYLACTIC ACID; TISSUE SCAFFOLD;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL GRAFT; CELL LOSS; EMBRYONIC STEM CELL; HEART SURGERY; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; MACROPHAGE; MONONUCLEAR CELL; NEOINTIMA; NONHUMAN; STENOSIS; THROMBOSIS; TISSUE ENGINEERING; ANIMAL; BLOOD VESSEL PROSTHESIS; HEART MUSCLE REVASCULARIZATION; METHODOLOGY; REVIEW;

ANIMALS; BLOOD VESSEL PROSTHESIS; HUMANS; MYOCARDIAL REVASCULARIZATION; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84873741315     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0044     Document Type: Article

References (47)

1. Petrossian E, Reddy VM, Collins KK et al. The extracardiac conduit Fontan operation using minimal approach extracorporeal circulation: Early and midterm outcomes. J Thorac Cardiovasc Surg 2006;132:1054-1063.
2. Wang X, Lin P, Yao Q et al. Development of small-diameter vascular grafts. World J Surg 2007;31:682-689.
3. Twine CP, McLain AD. Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst Rev 2010:CD001487.
4. Giannico S, Hammad F, Amodeo A et al. Clinical outcome of 193 extracardiac Fontan patients: The first 15 years. J Am Coll Cardiol 2006;47:2065-2073.
5. Petrossian E, Reddy VM, McElhinney DB et al. Early results of the extracardiac conduit Fontan operation. J Thorac Cardiovasc Surg 1999;117:688-696.
6. Shinoka T, Breuer C. Tissue-engineered blood vessels in pediatric cardiac surgery. Yale J Biol Med 2008;81:161-166.
7. Dearani JA, Danielson GK, Puga FJ et al. Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac Surg 2003;75:399-410; discussion 410-391.
8. Holst KA, Dearani JA, Burkhart HM et al. Risk factors and early outcomes of multiple reoperations in adults with congenital heart disease. Ann Thorac Surg 2011;92:122-128; discussion 129-130.
9. Homann M, Haehnel JC, Mendler N et al. Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts. Eur J Cardiothorac Surg 2000;17:624-630.
10. Stark J. The use of valved conduits in pediatric cardiac surgery. Pediatr Cardiol 1998; 19:282-288.
11. Cleveland DC, Williams WG, Razzouk AJ et al. Failure of cryopreserved homograft valved conduits in the pulmonary circulation. Circulation 1992;86:II150-II153.
12. Jonas RA, Freed MD, Mayer JE, Jr., et al. Long-term follow-up of patients with synthetic right heart conduits. Circulation 1985;72:II77-II83.
13. Shinoka T, Shum-Tim D, Ma PX et al. Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg 1998;115:536-545; discussion 545-536.
14. Noishiki Y, Tomizawa Y, Yamane Y et al. Autocrine angiogenic vascular prosthesis with bone marrow transplantation. Nat Med 1996; 2:90-93.
15. Matsumura G, Miyagawa-Tomita S, Shin'Oka T et al. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation 2003;108:1729-1734.
16. Shinoka T, Imai Y, Matsumura G. Current status of tissue engineering for therapeutic use [in Japanese]. Nihon Rinsho 2001;59:1389-1399.
17. Lee J, Cuddihy MJ, Kotov NA. Three-dimensional cell culture matrices: State of the art. Tissue Eng Part B Rev 2008;14:61-86.
18. Quint C, Kondo Y, Manson RJ et al. Decellularized tissue-engineered blood vessel as an arterial conduit. Proc Natl Acad Sci USA 2011; 108:9214-9219.
19. Villalona GA, Udelsman B, Duncan DR et al. Cell-seeding techniques in vascular tissue engineering. Tissue Eng Part B Rev 2010;16: 341-350.
20. Udelsman B, Hibino N, Villalona GA et al. Development of an operator-independent method for seeding tissue-engineered vascular grafts. Tissue Eng Part C Methods 2011;17: 731-736.
21. Pawlowski KJ, Rittgers SE, Schmidt SP et al. Endothelial cell seeding of polymeric vascular grafts. Front Biosci 2004;9:1412-1421.
22. Cho SW, Lim SH, Kim IK et al. Small-diameter blood vessels engineered with bone marrow-derived cells. Ann Surg 2005;241:506-515.
23. Hashi CK, Zhu Y, Yang GY et al. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci USA 2007;104: 11915-11920.
24. Weber B, Emmert MY, Schoenauer R et al. Tissue engineering on matrix: Future of autologous tissue replacement. Semin Immunopathol 2011;33:307-315.
25. Dahl SL, Kypson AP, Lawson JH et al. Readily available tissue-engineered vascular grafts. Sci Transl Med 2011;3:68ra9.
26. Rashid ST, Salacinski HJ, Fuller BJ et al. Engineering of bypass conduits to improve patency. Cell Prolif 2004;37:351-366.
27. Hibino N, Nalbandian A, Devine L et al. Comparison of human bone marrow mononuclear cell isolation methods for creating tissueengineered vascular grafts: Novel filter system versus traditional density centrifugation method. Tissue Eng Part C Methods 2011;17: 993-998.
28. Germani A, Di Campli C, Pompilio G et al. Regenerative therapy in peripheral artery disease. Cardiovasc Ther 2009;27:289-304.
29. Lerou PH, Daley GQ. Therapeutic potential of embryonic stem cells. Blood Rev 2005; 19:321-331.
30. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
31. Raya A, Rodriguez-Piza I, Aran B et al. Generation of cardiomyocytes from new human embryonic stem cell lines derived from poor-quality blastocysts. Cold Spring Harbor Symp Quant Biol 2008;73:127-135.
32. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147.
33. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 2011;471:46-47.
34. Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212-215.
35. Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ Res 2011;109:720-721.
36. Hibino N, McGillicuddy E, Matsumura G et al. Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg 2010;139:431-436, 436.e1-2.
37. Naito Y, Shinoka T, Duncan D et al. Vascular tissue engineering: Towards the next generation vascular grafts. Adv Drug Deliv Rev 2011;63:312-323.
38. Shin'Oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary artery. N Engl J Med 2001;344:532-533.
39. Brennan MP, Dardik A, Hibino N et al. Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model. Ann Surg 2008;248:370-377.
40. Lopez-Soler RI, Brennan MP, Goyal A et al. Development of a mouse model for evaluation of small diameter vascular grafts. J Surg Res 2007;139:1-6.
41. Goyal A, Wang Y, Su H et al. Development of a model system for preliminary evaluation of tissue-engineered vascular conduits. J Pediatr Surg 2006;41:787-791.
42. Breuer CK. The development and translation of the tissue-engineered vascular graft. J Pediatr Surg 2011;46:8-17.
43. Roh JD, Sawh-Martinez R, Brennan MP et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci USA 2010; 107:4669-4674.
44. Hibino N, Yi T, Duncan DR et al. A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J 2011;25: 4253-4263.
45. Vogel G. Tissue engineering: Mending the youngest hearts. Science 2011;333:1088-1089.
46. Dolgin E. Taking tissue engineering to heart. Nat Med 2011;17:1032-1035.
47. Mima Y, Fukumoto S, Koyama H et al. Enhancement of cell-based therapeutic angiogenesis using a novel type of injectable scaffolds of hydroxyapatite-polymer nanocomposite microspheres. PLoS One 2012;7: e35199.